CenterBook Partners LP has disclosed its latest holdings in a recent 13F-HR filing, reporting a total value of $2,180,862,846 across 855 positions as of September 30, 2026. This substantial portfolio highlights the firm’s investment strategies and positions within the financial markets.

Founded and based in Greenwich, Connecticut, CenterBook Partners LP is an investment management firm that operates in the financial services sector. The firm’s recent filings include multiple 13F-HR reports, with the latest submitted on November 2, 2026. The firm is known for its strategic investments across various sectors, although specific SIC or industry descriptions were not provided in the filing.

The filing reveals a diverse range of investments, including notable holdings in companies such as 10X Genomics Inc, 3M Co, and Abbott Laboratories, among others. Each investment is reported with details on the number of shares held and the total value attributed to each position. For example, the firm holds 5,045 shares of 10X Genomics valued at approximately $455,866 and 16,557 shares of 3M Co valued at around $2,717,832.

CenterBook’s investment strategy appears to focus on a wide array of sectors, indicating a diversified approach to asset management. The firm’s total reported value of over $2.18 billion suggests a significant level of assets under management, which may position it as a key player in the investment management landscape.

This filing may have implications for various stakeholders, including investors, analysts, and competitors in the investment management industry. By disclosing its holdings, CenterBook provides insight into its investment philosophy and market outlook, which could influence market trends and investor behavior.

Looking ahead, it is expected that CenterBook will continue to file its 13F-HR reports quarterly, providing ongoing updates on its investment positions and strategies. The next filing is anticipated to reflect changes in the firm’s portfolio and investment approach, as market conditions evolve.